RGEN: Repligen Corporation Stock

by  •  • Comments Off on RGEN: Repligen Corporation Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 6,633.07
Enterprise Value ($M) 6,465.45
Book Value ($M) 1,985.48
Book Value / Share 35.34
Price / Book 3.34
NCAV ($M) 165.81
NCAV / Share 2.95
Price / NCAV 40.01

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.01

Liquidity (mrq)
Quick Ratio 5.79
Current Ratio 6.79

Balance Sheet (mrq) ($M)
Current Assets 1,032.46
Assets 2,852.14
Liabilities 866.66
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 634.44
Operating Income 44.96
Net Income -25.51
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 175.39
Cash from Investing -86.38
Cash from Financing -82.90

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-24 13G/A BlackRock, Inc. 9.30 -26.86
02-14 13G/A Price T Rowe Associates Inc /md/ 12.70 11.64
02-13 13G/A Eddleman Roy T 4.84 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-30 130,529 903,452 14.45
2025-05-29 158,620 968,509 16.38
2025-05-28 81,628 456,256 17.89
2025-05-27 142,325 512,331 27.78

(click for more detail)

Similar Companies
RDUS – Radius Recycling, Inc. REGN – Regeneron Pharmaceuticals, Inc.
REPL – Replimune Group, Inc. RGNX – REGENXBIO Inc.
RIGL – Rigel Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io